Trial Profile
A retrospective study comparing alemtuzumab with fingolimod in RRMS patients after switch from natalizumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 May 2019
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 21 Nov 2017 New trial record
- 28 Oct 2017 Results assessing the efficacy and safety of alemtuzumab versus fingolimod in RRMS patients after switch from natalizumab, were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.